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Abstract 
Hepatitis B infection is endemic in many developing countries including Ghana. It is also known that there are  
differences in  the  prevalence in  communities of  different  socioeconomic levels.  This  study  was 
conducted in a suburb of Accra to determine the relative seroprevalence of hepatitis B. Serum samples were 
collected between January and February 2015 during a cross-sectional survey of individuals from Adenta and 
tested for Hepatitis B surface antigen (HBsAg) using a commercial test kit (One Step HBsAg Test Device, 
InTEC Products, INC, China) after obtaining their informed consent. A total of 240 subjects had their 
samples collected for testing. There were 140 males and 100 females. A higher prevalence of HBsAg 
seropositivity was detected among the males as compared to the females. Majority of the participants were 
knowledgeable of the virus but most had not been vaccinated against the virus due to the high cost of the 
vaccine. In general, the seroprevalence of HBsAg was found to be low within the community. 
Keywords: Seroprevalence, HBsAG, Vaccine, Seropositive 
 
1. Introduction 
Hepatitis refers to a group of viral infections that affect the liver. There are five main hepatitis viruses, referred 
to as types A, B, C, D, and E. The most common types are the A, B, and C.    Most of the people infected with 
these viruses are unaware of their infection because viral hepatitis, particularly Hepatitis B virus, can persist for 
decades without symptoms. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B 
virus. It is a major global health problem. It can cause chronic liver disease and chronic infection and puts 
people at high risk of death from cirrhosis of the liver and liver cancer. Hepatitis B virus (HBV) infection is 
associated with a wide variety of clinical manifestations including jaundice, hepatomegaly, anorexia, 
abdominal and gastric discomfort, etc. [4,7]. First discovered in 1967, HBV of the Hapadnaviridae family is a 
human blood-borne virus which is strictly hepatotropic [2-13]. 
 
Most people with chronic hepatitis B in Ghana were infected at birth or in childhood. Hepatitis B is often framed 
as a sexually transmitted infection among medical and public health sectors. This inconsistency has significant 
implications for its treatment and monitoring. Communities play an important role in providing information 
about hepatitis B. Communities most affected by chronic hepatitis B in Ghana are often affected by the virus 
in a context of highly disrupted lives; where access to health care services may have been non-existent, and 
where hepatitis B is not seen as a priority. People with hepatitis B report no pre or post test discussion and little 
or no information is provided at the point of diagnosis. This fundamentally affects how people with hepatitis B 
understand and respond to their infection. People with hepatitis B often report their diagnosis as shocking with 
little understanding of how infection occurred or the implications of being infected. Few resources are available 
for people with hepatitis B or their families that would assist in understanding their infection and how to 
promote their health and well-being. 
 
Hepatitis B is a major cause of liver disease worldwide [11]. Despite education, campaigns and availability of 
effective drugs e.g. interferon alpha, lamivudine, adefovir [14] and vaccines [17], the disease is still a major 
global health problem. A vaccine against hepatitis B has been available since 1982. Hepatitis B vaccine is 95% 
effective in preventing infection and its chronic consequences, and was the first vaccine against  a  major  
human  cancer.  Transfusion of  infected  blood,  unprotected sex  and  mother  to  child transmission are 3 
key transmission routes of HBV in Ghana [15].   Hepatitis B is a contagious disease. Transfusion - 
transmitted HBV infection has become a major mode of transmission of HBV in high prevalence areas in sub 
Saharan Africa [10]. Blood safety therefore remains an issue of major concern in transfusion medicine in Sub 
Saharan Africa [10]. There is high incidence of blood-demanding health situations in Ghana resulting from 
anemia, malnutrition, accidents, surgical and obstetrical emergencies associated with blood loss, etc. The 
higher the demand for blood transfusion services, the higher the possibility of transmitting Hepatitis B virus 
and other blood-borne pathogens through contaminated blood. Illiteracy, lack of adequate health information, 
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low socioeconomic situation in the region, inadequate trained health personnel and some inappropriate cultural 
practices linked with transmission dynamics including polygamy tend to augment the disease transmission. 
 
There is high prevalence of Hepatitis B virus (approx. 30%) among blood donors therefore for those infected 
with Hepatitis B virus, appropriate management has been shown to substantially reduce the risk of long-term 
liver damage, including cirrhosis and liver cancer. 
 
Approximately, two million people contract hepatitis from unsafe injections annually. These infections can be 
averted through the use of sterile syringes that are specifically designed to prevent reuse [16]. 
The vaccine has an excellent record of safety and effectiveness. Since 1982, over one billion doses of hepatitis 
B vaccine have been used worldwide. In many countries, where 8–15% of children used to become 
chronically infected with the hepatitis B virus, vaccination has reduced the rate of chronic infection to less than 
1% among immunized children. 
Many practitioners however lack the adequate knowledge to identify individuals at risk of infection, thus 
hepatitis B remains under-diagnosed in Ghana. It is also under-treated, as many physicians lack sufficient 
knowledge of the pathways of care that are available to patients infected with Hepatitis B virus, limiting their 
ability to offer individualized advice to their patients. 
Viral hepatitis should be considered as an urgent public health issue, and a comprehensive strategy (of course, 
in collaboration with the WHO and other development partners) is needed to prevent and control viral hepatitis 
on the continent.  Recently, there has been greater awareness and education on the topic. 
 
This study therefore was conducted to determine the impact of public education on the prevalence of hepatitis 
B infection among individuals living within the Adentan municipality of the Greater Accra region of Ghana 
and to propose possible interventions that will help minimize or possibly eliminate the infection in Ghana. 
 
2. METHODOLOGY 
2.1   Study design and population 
The study was a cross-sectional survey and participants included all individuals who reside within the Adenta 
municipality that consented to participate in the study. The study recruited 240 individuals comprising 140 
males and 100 females between the ages of 18 and 50 during the period of January and Feb ruary 2015. 
 
2.2   Collection and processing of specimen 
A 2ml syringe and needle were used to bleed approximately 2 ml of blood from each donor, transferred into a 
vacutainer and centrifuged at 1500 rpm for 3 minutes to obtain serum. A test strip was immersed in each 
serum. The strips were removed after 10 seconds and placed on a dry clean non-absorbent table surface for 15 
minutes after which they were visualized. 
 
2.3    Interpretation of results 
The test results were interpreted based on the following principles; 
Negative test for HBV: Only one colored band appears on the control (C) region. 
Positive test for HBV: In addition to a pink colored control (C) band, a distinct pink colored band also 
appears in the test (T) region. 
Invalid test for HBV: A total absence of color in both regions. 
 
2.4   Questionnaire 
A well-structured questionnaire was used to collect date regarding some demographic characteristics of the 
participants and some lifestyles. 
 
2.5   Statistical analysis 
Results were computed in graphs and tables using Microsoft Excel and Microsoft word on the Microsoft 
Office 2010 package. The data was analyzed using SPSS and Stata (version 11.2) statistical package set at 
95% Confidence Interval (and a p-value < 0.05 as considered statistically significant). 
 
3. RESULTS 
Out of 240 participants, 140 were male (58.3%) with 5 testing positive to the virus whiles the remaining 
100 were female (41.7%) with 3 testing positive to the virus, thus making a total of 8 positive cases (3.3% 
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prevalence) (figure 1). 234 (97.5%) participants indicated that they were quite knowledgeable about the virus 
and its menace while 6 (2.5%) participants admitted ignorance of the virus and its activities. The educational 
status (table 1) of the participants has little or no bearing on the infection. There was a significant correlation 
between the knowledge of the virus and the infection (p=0.000). 20 (8.3%) of the participants claimed to have 
been sexually inactive for the past ten years while 189 (78.8%) participants claimed to having only one sexual 
partner at a time for the past ten years. However, 31 (12.9%) participants admitted to having multiple partners 
within the last ten years most often at the same time. 6 of the participants who tested positive to the virus were 
among those with multiple partners while the other 2 participants were among those who have had no sexual 
partner within the last ten years. 49 (20.4%) participants in the study had received the complete dose of the 
vaccine against the virus before the study while the remaining 191 (79.6%) had not been vaccinated before the 
study. 
 
 
Figure 1: Prevalence of Hepatitis B amongst the participants 
 
 
 
Table 1: Educational status of participants in the study 
 
Level of education Percentage 
Primary 17.5 
Junior high school 16.7 
Senior high school 23.8 
Tertiary 17.9 
Other (vocational) 17.1 
No formal education 7.0 
Total 100 
 
4. DISCUSSION 
The One Step HBsAg Test is a qualitative immunoassay that detects HBsAg in blood serum. The decline in 
the seroprevalence of Hepatitis B virus infection in this study is in conflict with some studies conducted in 
rural areas in developing countries where it was considered endemic [6,8,9,12,20]. The low prevalence (3.3%) 
obtained during the study among the participants suggests the hepatitis B education is yielding positive results. 
However, the high cost of the testing and vaccination may have contributed to more than 2/3 of the 
participants not being vaccinated. Most developing countries are facing multiple threats to the safety of blood 
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supply because the cost of HBsAg screening is borne by the patients and  their  families  who  do  not  enjoy 
health coverage  [1].  Generally also,  there  is  no  prevention of transmission between mother and child. A 
survey conducted in the northern region of Ghana showed that the high prevalence of HBsAg markers in 
donors who were >10 years was consistent with the concept that most primary Hepatitis B virus infections 
were transmitted either vertically or horizontally before age 10 [5].   This may account for the two 
participants who had no sexual partners within the last ten years but tested positive to the virus. Other factors 
such as blood transfusion may also play a role in the acquisition of the virus. The reason for the slight gender 
imbalance, i.e. more males (140) than females (100), cannot be directly inferred from this data; however, 
within the context of the study area, the males were more proactive and independent in decision making 
and volunteering than the females. This probably explains the slight difference in gender. The literacy rate of 
the people in the study area was well above average but this had no significant bearing on the reduced 
prevalence of the virus. Public sensitization/awareness about the viral disease and its mode of transmission 
may have contributed to the relatively low prevalence of Hepatitis B virus infection. In Ghana, local 
prevalence of the disease may vary widely, possibly as a consequence of lifestyle and socioeconomic variations 
even in closely related settlements. 
 
5. Conclusion 
The prevalence of Hepatitis B virus infection in the Adenta Municipality is low (3.3%). Notwithstanding 
this, it is important to note that proper management of hepatitis B requires a combination of: 
 
1. Prevention: vaccination of newborns is the most effective means of preventing hepatitis B. Targeted 
prevention of risk groups, accompanied by strong educational campaigns, is also important and should be 
strengthened. 
2. Screening of individuals at risk: Given the absence of symptoms in the early stages of hepatitis B, 
many individuals do not know that they are infected. Screening programme are thus necessary to contain the 
risk of infection by allowing individuals who are Hepatitis B virus -positive to follow the right course of care 
for themselves and take appropriate measures to avoid infecting others. 
3. Diagnosis and monitoring: Hepatitis B is under-diagnosed in Ghana. Once diagnosis is ascertained, it is 
critical that individuals are monitored regularly to determine whether the disease has progressed and whether 
treatment should be initiated. 
4. Treatment: There have been important advances in the development of antiviral therapies to treat 
patients with hepatitis B, as are reflected in recent WHO guidelines. Early treatment is critical to prevent the 
progression of liver disease. 
 
In order to further reduce the aforementioned prevalence, it is recommended that the Ghana Health Service and 
NGOs plan major Hepatitis B virus vaccination campaigns and educate people about risk factors for infection 
and benefits of immunization. 
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